thalidomide has been researched along with Anemia, Hemolytic in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Anemia, Hemolytic: A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thalidomide, lenalidomide and bortezomib have all been shown to be highly effective in multiple myeloma, and JAK2-inhibitors have entered phase II studies of patients with JAK2-positive primary myelofibrosis and related diseases." | 4.84 | [Novel medical treatment modalities in hematology]. ( Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, Y | 1 |
| Yang, K | 1 |
| Kong, W | 1 |
| Xiao, J | 1 |
| Liu, X | 1 |
| Lim, MY | 1 |
| Raval, JS | 1 |
| Richards, KL | 1 |
| Zeidner, JF | 1 |
| Foster, MC | 1 |
| Fozza, C | 1 |
| Pardini, S | 1 |
| Giannico, DB | 1 |
| Targhetta, C | 1 |
| Di Tucci, AA | 1 |
| Dessalvi, P | 1 |
| Angelucci, E | 1 |
| Dore, F | 1 |
| Hasselbalch, HC | 1 |
| Birgens, H | 1 |
| Dufva, IH | 1 |
| Dalseg, AM | 1 |
| Brown, Pde N | 1 |
| Jensen, MK | 1 |
| Vangsted, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia: a Quasi Randomized Control Trial in a Tertiary Care Hospital in Bangladesh[NCT06098014] | Phase 3 | 60 participants (Anticipated) | Interventional | 2023-03-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Anemia, Hemolytic
| Article | Year |
|---|---|
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antib | 2008 |
3 other studies available for thalidomide and Anemia, Hemolytic
| Article | Year |
|---|---|
Thalidomide-associated autoimmune hemolytic anemia.
Topics: Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Humans; Thalidomide | 2023 |
Lenalidomide-associated hemolytic anemia.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Huma | 2015 |
Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis.
Topics: Aged; Anemia, Hemolytic; Antibodies, Monoclonal, Murine-Derived; Blood Transfusion; Female; Hemolysi | 2015 |